Xueqing Liu
Principal Scientist @Avidity Biosciences, Inc.
Signup · Get unlimited contacts
WORK HISTORY
Principal Scientist @Avidity Biosciences, Inc.
San Diego County, CA, US
Clinical biomarker functional lead for clinical pharmacodynamics analysis for an antibody siRNA conjugate drug in a clinical trial for rare muscle disease FSHD- Support antibody oligonucleotide conjugate (AOC) drug discovery project in rare muscle diseases- Lead a clinical biomarker team in biomarker discovery, assay development and data analysis on AOC drug candidates to support clinical studies- Working experience with internal cross functional teams including clinical development, clinical operation, biometrics, clinical pharmacology, regulatory and toxicology functions to support a clinical trial- External collaboration with key opinion leaders (KOL) to overcome program challenges, managing CRO vendors for clinical assay development, assay transfer and qualification
EDUCATION
Ohio University
Doctor of Philosophy (Ph.D.), Biochemistry
University of Wisconsin-Madison
Postdoctoral, Metabolic disease
SKILLS
ABOUT XUEQING LIU
Thirteen years of industry experience in drug discovery and translational research in modalities including RNAi (antibody oligonucleotide conjugate or siRNA AOC), microRNA and small molecules.Clinical biomarker functional lead in clinical trial testing siRNA AOC for rare neuromuscular disease. New clinical biomarkers discovery, assay development, assay transfer, qualification and validation at clinical CRO lab. Review clinical trial documents: clinical study protocol, investigator\'s brochure (IB), informed consent form (ICF), Global Laboratory Specifications Document (GLSD), and biopsy manual. Working experience with cross functional teams such as clinical development, clinical operation, biometrics and regulatory, etc.Pre-clinical project lead for drug discovery to IND including target identification, in vitro and in vivo compound screening, mechanism of action examination and proof-of-concept data package.Human translational MOA study on FXR agonists using non-clinical models; Designing, communicating and managing outsourced pharmacology studies at CROs; In vivo pharmacology; pharmacodynamics (PD) and Pharmacokinetics (PK) study design and interpretation; In vitro and in vivo disease models development; Assay development of in vivo, ex vivo and in vitro cell-based assays;Expertise in therapeutic areas of metabolic, inflammatory, intestinal, liver and kidney diseases including inflammatory bowel disease (IBD), non-alcoholic steatohepatitis (NASH), liver fibrosis, diabetes, cardiovascular disease, orphan kidney fibrosis, ADPKD, obesity and neurodegenerative disease; Managed direct reporting scientists at different levels in a matrix team environment; Coordinated collaborative activities with external KOLs and CROs. Authorship of scientific publications in peer-reviewed high-profile journals.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.